Development Pipeline
  Commercial Products
  Research Programs







Product: Remoxy®
NDA
Indication: Chronic Pain
Drug: Oxycodone
Partner: Pain Therapeutics
Technology: ORADUR® (sustained release oral gel-cap)

Product: POSIDUR™
Phase II
Indication: Post-Operative Pain
Drug: Bupivacaine
Partner: Worlwide rights held by DURECT
Technology: SABER® Delivery System (injectable)

Product: DUR-928
Phase I
Indication: Metabolic diseases and acute organ injuries
Drug: An endogenous small molecule
Partner: Worldwide rights held by DURECT
Technology: New chemical entity

Product: ELADUR® (TRANSDUR®-Bupivacaine)
Phase I
Indication: Post-Herpetic Neuralgia
Drug: Bupivacaine
Partner: Impax
Technology: TRANSDUR Delivery System

Product: ORADUR-based Hydromorphone
Phase I
Indication: Chronic Pain
Drug: Hydromorphone
Partner: Pain Therapeutics
Technology: ORADUR® (sustained release oral gel-cap)

Product: ORADUR®-ADHD
Phase I
Indication: Attention Deficit Hyperactivity Disorder
Drug: Undisclosed
Partner: Orient Pharma (certain Asian countries)
Technology: ORADUR® (sustained release oral gel-cap)

Product: Relday™ (risperidone)
Phase I
Indication: Schizophrenia and Bipolar Disorder
Drug: Risperidone
Partner: Zogenix
Technology: SABER® Delivery System


Product: Santen Ophthalmology Product
Pre-Clinical
Indication: Ophthalmology
Drug: Undisclosed
Partner: Santen Pharmaceutical Co., Ltd.
Technology: SABER® Delivery System (injectable)



 
 © 2000-2015 DURECT Corporation
Last updated: April 01, 2015
Search     Contact     Site Index     Legal Notice     Privacy Policy